HK1214523A1 - 醋酸格拉替雷的透粘膜给药 - Google Patents

醋酸格拉替雷的透粘膜给药 Download PDF

Info

Publication number
HK1214523A1
HK1214523A1 HK16102544.9A HK16102544A HK1214523A1 HK 1214523 A1 HK1214523 A1 HK 1214523A1 HK 16102544 A HK16102544 A HK 16102544A HK 1214523 A1 HK1214523 A1 HK 1214523A1
Authority
HK
Hong Kong
Prior art keywords
glatiramer acetate
transmucosal delivery
percent
weight
provides
Prior art date
Application number
HK16102544.9A
Other languages
English (en)
Chinese (zh)
Inventor
Geister Ursula
Schweizer Stephan
Buerger Martina
Stefan Ralph
Huber Gerald
Pries Tanja
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HK1214523A1 publication Critical patent/HK1214523A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16102544.9A 2012-12-21 2013-12-20 醋酸格拉替雷的透粘膜给药 HK1214523A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745226P 2012-12-21 2012-12-21
US61/745,226 2012-12-21
PCT/US2013/077034 WO2014100639A1 (en) 2012-12-21 2013-12-20 Transmucosal delivery of glatiramer acetate

Publications (1)

Publication Number Publication Date
HK1214523A1 true HK1214523A1 (zh) 2016-07-29

Family

ID=50979257

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16102544.9A HK1214523A1 (zh) 2012-12-21 2013-12-20 醋酸格拉替雷的透粘膜给药
HK16102020.2A HK1214134A1 (zh) 2012-12-21 2013-12-20 醋酸格拉替雷的透粘膜给药

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16102020.2A HK1214134A1 (zh) 2012-12-21 2013-12-20 醋酸格拉替雷的透粘膜给药

Country Status (15)

Country Link
US (1) US20160193276A1 (enExample)
EP (1) EP2934492A4 (enExample)
JP (1) JP2016503803A (enExample)
KR (1) KR20150111918A (enExample)
CN (1) CN104869983A (enExample)
AU (1) AU2013361053A1 (enExample)
BR (1) BR112015014095A2 (enExample)
CA (1) CA2895359A1 (enExample)
EA (1) EA201591188A1 (enExample)
HK (2) HK1214523A1 (enExample)
IL (1) IL239280A0 (enExample)
MX (1) MX2015007678A (enExample)
SG (1) SG11201504422XA (enExample)
WO (1) WO2014100639A1 (enExample)
ZA (1) ZA201505049B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
MX2014004309A (es) 2011-10-10 2015-07-06 Teva Pharma Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US10493122B2 (en) 2014-03-17 2019-12-03 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
CN106924175B (zh) * 2015-12-29 2020-07-03 深圳翰宇药业股份有限公司 一种治疗多发性硬化症的药物组合物
JP6931884B2 (ja) * 2016-02-12 2021-09-08 テイカ製薬株式会社 乾式造粒物及び該乾式造粒物を含有する固形製剤並びにそれらの製造方法
US10323289B2 (en) 2017-06-26 2019-06-18 Institut Pasteur Treatments to eliminate HIV reservoirs and reduce viral load

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02008023A (es) * 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
US7022663B2 (en) * 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
JP4426286B2 (ja) * 2001-07-10 2010-03-03 テバ ファーマシューティカル インダストリーズ リミティド ０次、０次−二相性、上昇型又は下降型薬物放出のための薬物送達システム
RS52867B (sr) * 2005-02-17 2013-12-31 Teva Pharmaceutical Industries Ltd. Kombinovana terapija glatiramer acetatom i razagilinom za lečenje multiple skleroze
JP2009515956A (ja) * 2005-11-22 2009-04-16 テバ ファーマシューティカル インダストリーズ リミティド テルミサルタンの医薬組成物
WO2007074472A2 (en) * 2005-12-27 2007-07-05 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide
EP2529621B1 (en) * 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.

Also Published As

Publication number Publication date
EP2934492A1 (en) 2015-10-28
AU2013361053A1 (en) 2015-07-30
EA201591188A1 (ru) 2016-04-29
MX2015007678A (es) 2015-09-07
EP2934492A4 (en) 2016-08-17
KR20150111918A (ko) 2015-10-06
HK1214134A1 (zh) 2016-07-22
BR112015014095A2 (pt) 2017-07-11
JP2016503803A (ja) 2016-02-08
WO2014100639A1 (en) 2014-06-26
CN104869983A (zh) 2015-08-26
ZA201505049B (en) 2016-10-26
SG11201504422XA (en) 2015-07-30
US20160193276A1 (en) 2016-07-07
CA2895359A1 (en) 2014-06-26
IL239280A0 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
MX2015007678A (es) Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales.
PH12015501439A1 (en) Oral care products comprising zinc oxide and trimethylglycine
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
IL222268A (en) Preserved pyrollo-pyridines, containing pharmaceutical preparations, combined preparations containing them and their use in the preparation of medicines
AU2009303344A8 (en) Targeting of antigen presenting cells with immunonanotherapeutics
PH12013500513A1 (en) Nanocapsules containing microemulsions
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
WO2012174158A3 (en) Administration of benzodiazepine
PH12017501688A1 (en) Intranasal benzodiazepine pharmaceutical compositions
MX348823B (es) Formulaciones estables de linaclotida.
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2013013204A (es) Sistema de suministro de farmaco.
IN2014CN03214A (enExample)
HK1214522A1 (zh) 醋酸格拉默的口腔透黏膜给药
IT1400837B1 (it) Metodo per la preparazione e uso di biocidi arricchiti in radicali attivi prima dell'uso.
MX360047B (es) Unidad sólida con alto contenido en fexofenadina y su procedimiento de preparación.
WO2011128634A3 (en) Over the counter pharmaceutical compositions
UA105944C2 (uk) Комбінація теоброміну з деконгестантом і її застосування для лікування кашлю
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
WO2011161223A3 (en) Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
IN2012CH05549A (enExample)
HK1181303A (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
CA143686S (en) Buccal medication delivery device adapter
UA65795U (ru) Способ профилактики преэклампсии при многоплодии